The infectious disease drugs market size is mainly driven by rising prevalence of the infectious diseases across the globe. Extensive research activities being carried out by the major industry players is driving the business growth rate during the foreseeable period. Furthermore, launch of novel drugs in the marketplace such as direct acting antivirals will further support in improving industry revenue generation till 2028.
In addition, the developing countries such as India and China, government initiatives and several programs are launched to promote awareness related to infectious diseases nationally. These initiatives will supplement the market growth over the study period. Increasing number of product launches and rise in merger and acquisitions among the industry players are the emerging trends of the global infectious disease drugs business. However, expiry of the patent products followed by rising preference for generic drugs may slowdown the business improvement between 2022 and 2027.
The infectious disease drugs market is segmented on the lines of its disease, treatment, end-use and regional. The basis of disease the market is segmented into Bacterial Disease, Viral Disease, Fungal Disease, and Parasitic Disease. Based on treatment the global infectious disease drugs market covers Antibacterial, Antifungal, Antiviral, Antiparasitic, and Alternative Medicine. On the basis of distribution channel, the market is segregated into Pharmacies, Grocery Stores, Vitamin & Health Food Stores, and Online Pharmacies. The infectious disease drugs market on geographic segmentation covers various regions such as North America, Europe, Asia Pacific, and Rest of World. Each geographic market is further segmented to provide market revenue for selected countries such as the U.S., Canada, Germany, UK, France, Italy, China, India, Japan, Brazil, South Africa and others.
Competitive Rivalry
F. Hoffmann-La Roche, AstraZeneca, Bayer AG, GlaxoSmithKline, Pfizer, Gilead Sciences, Bristol-Myers Squibb Company, Sanofi, Merck, Johnson & Johnson, Novartis, AbbVie and Auritec Pharmaceuticals are among the major players in the global infectious disease drugs market share. The companies are involved in several growth and expansion strategies to gain a competitive advantage. Industry participants also follow value chain integration with business operations in multiple stages of the value chain.
The Infectious Disease Drugs Market has been segmented as below:
Infectious Disease Drugs Market, By Disease
Infectious Disease Drugs Market, By Treatment
Infectious Disease Drugs Market, By Distribution Channel
Infectious Disease Drugs Market, By Region
The report covers:
Report scope:
The scope of the report includes a detailed study of infectious disease drugs market with the reasons given for variations in the growth of the industry in certain regions.
The report covers a detailed competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled in the report include F. Hoffmann-La Roche, AstraZeneca, Bayer AG, GlaxoSmithKline, Pfizer, Gilead Sciences, Bristol-Myers Squibb Company, Sanofi, Merck, Johnson & Johnson, Novartis, AbbVie and Auritec Pharmaceuticals. Company profile includes assigning such as company overview, product landscape, financial overview, and recent developments.
The top company reports are intended to provide our buyers with a snapshot of the industry’s most influential players.
Reasons to Buy this Report:
Customization:
We can offer you custom research reports as per client’s special requirements
Below are our New Reports :-
Robotic Pharmacy Prescription Dispensing Systems Market
1. Introduction
1.1. Key Points
1.2. Report Description
1.3. Markets Covered
1.4. Stakeholders
2. Research Methodology
2.1. Research Scope
2.2. Research Methodology
2.2.1. Market Research Process
2.2.2. Research Methodology
2.2.2.1. Secondary Research
2.2.2.2. Primary Research
2.2.2.3. Models for Estimation
2.3. Market Size Estimation
2.3.1. Bottom-Up Approach
2.3.2. Top-Down Approach
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Drivers
4.2.1. Rising prevalence of infectious diseases
4.2.2. Patent expiration of branded drugs
4.2.3. Driver 3
4.3. Restraints
4.3.1. Lack of reimbursement in developing countries
4.4. Opportunities
4.4.1. Increasing funding activities by various organizations
4.4.2. Upsurge in awareness activities by non-profit organization
4.5. Challenges
4.5.1. Less penetration of diagnosis and treatment
5. Infectious Disease Drugs Market, By Disease
5.1. Key Points
5.2. Bacterial Disease
5.3. Viral Disease
5.4. Fungal Disease
5.5. Parasitic Disease
6. Infectious Disease Drugs Market, By Treatment
6.1. Key Points
6.2. Antibacterial
6.3. Antifungal
6.4. Antiviral
6.5. Antiparasitic
6.6. Alternative Medicine
7. Infectious Disease Drugs Market, By Distribution Channel
7.1. Key Points
7.2. Pharmacies
7.3. Grocery Stores
7.4. Vitamin & Health Food Stores
7.5. Online Pharmacies
7.6. Others
8. Competitive Landscape
8.1. Introduction
8.2. Recent Developments
8.2.1. Mergers & Acquisitions
8.2.2. New Product Developments
8.2.3. Portfolio/Production Capacity Expansions
8.2.4. Joint Ventures, Collaborations, Partnerships & Agreements
8.2.5. Others
9. Company Profile
9.1. F. Hoffmann-La Roche
9.1.1. Company Overview
9.1.2. Product/Service Landscape
9.1.3. Financial Overview
9.1.4. Recent Developments
9.2. AstraZeneca
9.2.1. Company Overview
9.2.2. Product/Service Landscape
9.2.3. Financial Overview
9.2.4. Recent Developments
9.3. Bayer AG
9.3.1. Company Overview
9.3.2. Product/Service Landscape
9.3.3. Financial Overview
9.3.4. Recent Developments
9.4. GlaxoSmithKline
9.4.1. Company Overview
9.4.2. Product/Service Landscape
9.4.3. Financial Overview
9.4.4. Recent Developments
9.5. Pfizer
9.5.1. Company Overview
9.5.2. Product/Service Landscape
9.5.3. Financial Overview
9.5.4. Recent Developments
9.6. Gilead Sciences
9.6.1. Company Overview
9.6.2. Product/Service Landscape
9.6.3. Financial Overview
9.6.4. Recent Developments
9.7. Bristol-Myers Squibb Company
9.7.1. Company Overview
9.7.2. Product/Service Landscape
9.7.3. Financial Overview
9.7.4. Recent Developments
9.8. Sanofi
9.8.1. Company Overview
9.8.2. Product/Service Landscape
9.8.3. Financial Overview
9.8.4. Recent Developments
9.9. Merck
9.9.1. Company Overview
9.9.2. Product/Service Landscape
9.9.3. Financial Overview
9.9.4. Recent Developments
9.10. Johnson & Johnson
9.10.1. Company Overview
9.10.2. Product/Service Landscape
9.10.3. Financial Overview
9.10.4. Recent Developments
9.11. Novartis
9.11.1. Company Overview
9.11.2. Product/Service Landscape
9.11.3. Financial Overview
9.11.4. Recent Developments
9.12. AbbVie
9.12.1. Company Overview
9.12.2. Product/Service Landscape
9.12.3. Financial Overview
9.12.4. Recent Developments
9.13. Auritec Pharmaceuticals
9.13.1. Company Overview
9.13.2. Product/Service Landscape
9.13.3. Financial Overview
9.13.4. Recent Developments
The Infectious Disease Drugs Market has been segmented as below:
Infectious Disease Drugs Market, By Disease
Infectious Disease Drugs Market, By Treatment
Infectious Disease Drugs Market, By Distribution Channel
Infectious Disease Drugs Market, By Region
SUBSCRIBE TO OUR NEWSLETTERS
